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Background: Traumatic brain injury (TBI) is a major public health concern and many people develop long-lasting
physical and neuropsychiatric consequences following a TBI. Despite the emphasis on physical rehabilitation, it is
the emotional and behavioural consequences that have greater impact on people with TBI and their families. One
such problem behaviour is aggression which can be directed towards others, towards property or towards the self.
Aggression is reported to be common after TBI (37–71%) and causes major stress for patients and their families.
Both drug and non-drug interventions are used to manage this challenging behaviour, but the evidence-base for
these interventions is poor and no drugs are currently licensed for the treatment of aggression following TBI. The
most commonly used drugs for this purpose are antipsychotics, particularly second-generation drugs such as
risperidone. Despite this widespread use, randomised controlled trials (RCTs) of antipsychotic drugs, including
risperidone, have not been conducted. We have, therefore, set out to test the feasibility of conducting an RCT of
this drug for people who have aggressive behaviour following TBI.
Methods/design: We will examine the feasibility of conducting a placebo-controlled, double-blind RCT of
risperidone for the management of aggression in adults with TBI and also assess participants’ views about their
experience of taking part in the study.
We will randomise 50 TBI patients from secondary care services in four centres in London and Kent to up to 4 mg
of risperidone orally or an inert placebo and follow them up 12 weeks later. Participants will be randomised to
active or control treatment in a 1:1 ratio via an external and remote web-based randomisation service. Participants
will be assessed at baseline and 12-week follow-up using a battery of assessment scales to measure changes in
aggressive behaviour (MOAS, IRQ) as well as global functioning (GOS-E, CGI), quality of life (EQ-5D-5L, SF-12) and
mental health (HADS). We will also assess the adverse effect profile with a standard scale (UKU) and collect available
data from medical records on blood tests (serum glucose/HbA1c, lipid profile, prolactin), and check body weight
and blood pressure. In addition completion of the MOAS and a check for any new or worsening side-effect will be
completed weekly and used by the prescribing clinician to determine continuing dosage. Family carers’ wellbeing
will be assessed with CWSQ. Service use will be recorded using CSRI. A process evaluation will be carried out at the
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end of the trial using both qualitative and quantitative methodology.
Discussion: Aggressive behaviour causes immense distress among some people with TBI and their families. By
examining the feasibility of a double-blind, placebo-controlled RCT, we aim to discover whether this approach can
successfully be used to test the effects of risperidone for the treatment of aggressive behaviour among people with
aggression following TBI and improve the evidence base for the treatment of these symptoms. Our criteria for
demonstrating success of the feasibility study are: (1) recruitment of at least 80% of the study sample, (2) uptake of
intervention by at least 80% of participants in the active arm of the trial and (3) completion of follow-up interviews
at 12 weeks by at least 75% of the study participants.
Trial registration: ISRCTN30191436. Registered on 19 December 2016.
Keywords: Traumatic brain injury, Aggression, Pharmacological intervention, Risperidone, Feasibility RCTBackground
Traumatic brain injury (TBI) is a major public health
concern in the UK. Each year, 1.4 million people attend
hospitals in England and Wales with a recent TBI (about
80% have mild TBI) of them around 200,000 people are
admitted to hospital [1, 2]. More and more patients with
TBI are surviving longer now because of improved med-
ical and surgical treatment of their injuries. However, it
has been shown that long-term consequences are com-
mon after TBI of all severity. Thornhill and colleagues
(2000) [3] showed that, of patients admitted to hospital
with TBI, 86% of those who had sustained a severe TBI,
62% of those who had sustained a moderate TBI and
55% of those who had sustained a mild TBI had physical
and emotional problems 1 year after their injury. In the
first-ever comprehensive assessment of neuropsychiatric
consequences after TBI we found that 32% of patients
aged 18–65 years had suffered from a psychiatric dis-
order in the year following their injury, compared to
16% of the general population [4–7].
Of all the neurobehavioural problems following TBI,
aggression remains the most challenging. The long-term
prevalence of aggressive behaviour following mild to se-
vere TBI varies between 37% and 71% according to dif-
ferent studies [8, 9]. Aggression affects quality of life of
both the patients and their family carers and remains
the most difficult problem clinically to manage. Both
pharmacological and non-pharmacological interventions
are used to manage this difficult behaviour in practice.
However, scientific evidence to suggest that any interven-
tion works is lacking. Our systematic review [10] and a re-
cent Cochrane review [11] showed lack of good-quality
randomised control trials (RCTs) in this field. While very
small-scale RCTs (involving only 21, 11 and 4 participants,
respectively) of high doses of propranalol have been con-
ducted, concerns about adverse events of these drugs at a
high dose means that they are not widely used in clinical
practice. The most commonly used groups of drugs in
TBI are antipsychotics and mood stabilisers/antiepileptic
medications [12]. Among the antipsychotics, the newgeneration of drugs, such as risperidone, quetiapine, olan-
zapine and aripiprazole, are used more often than the old
generation of antipsychotics [13]. However, because of
lack of evidence and in the absence of any national/inter-
national guidelines, clinicians tend to choose antipsy-
chotics based on their, often limited, personal experience
and anecdotal evidence.
As risperidone is widely used in people with TBI for
the management of aggression and, is the only drug for
which there is some evidence of effectiveness in the
management of aggression in people with dementia, aut-
ism spectrum disorder (ASD) and intellectual disabilities
(ID), but as no such RCTs exist involving people with
TBI [14–17], we have chosen low-dose risperidone as
the active intervention drug for our placebo-controlled,
feasibility, double-blind RCT for people with TBI. Data
from this feasibility study will allow us to develop a full-
scale RCT in the future.
In keeping with MRC guidelines on the evaluation of
complex interventions, we will integrate a process evalu-
ation within this feasibility study [18]. We will explore
participants’ beliefs about the impact of the intervention
(including both positive and negative effects), mecha-
nisms of action, and factors that facilitate or hinder its
successful delivery.
Aims and objectives
(1) to improve the management of aggression among
people with TBI by providing evidence for a particular
pharmacological intervention, (2) to assess outcome at
12 weeks using the Modified Overt Aggression Scale
(MOAS) [19] as the primary outcome measure to assess
aggression in order to estimate sample size for future full
RCT, and gauge the potential recruitment and dropout
rates, (3) to conduct a multi-centre, parallel-design,
placebo-controlled (1:1 ratio), double-blind RCT of ris-
peridone for the management of aggression in adults
with TBI in order to assess feasibility for a substantive,
full-scale, definitive RCT in future and (4) to carry out a
process evaluation at the end of the RCT follow-up.
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The study will randomise up to 50 adults with TBI and ag-
gressive behaviour into risperidone and placebo groups in
equal numbers. The study is a four-centre, parallel-design,
double-blind, flexible-dose RCT. The current study will
allow us to assess a number of areas of feasibility, which
will determine the viability of undertaking a full-scale
RCT and ensure appropriate methodological design.
Inclusion criteria
(1) aged between 18 and 65 years, (2) a confirmed clin-
ical diagnosis of TBI which occurred at least 6 months
prior to recruitment, evidenced as a rating of moderate/
severe or mild (probable) based on Mayo Clinic criteria
[20], (3) referred to the clinician for the management of
aggression and for whom the clinician is considering a
pharmacological intervention for this problem after in-
vestigating and addressing physical, psychological and
social triggers and (4) competent and willing to provide
written, informed consent.
Exclusion criteria
(1) suffering from post-traumatic amnesia (PTA), (2)
co-morbid serious mental illness, such as schizophrenia
and other psychoses, bipolar disorder, major depressive
disorder, personality disorder and dementia, and where
the clinicians are treating primarily a psychiatric dis-
order rather than aggressive behaviour, (3) already pre-
scribed an antipsychotic drug or any other drug that
may interact with risperidone at the time of randomisa-
tion. A wash-out period of at least 2 weeks is required
prior to randomisation, (4) any other contraindication
for using risperidone including a previous history of se-
vere adverse events, (5) has no fixed abode or any other
reason for which compliance with trial medication and
monitoring could pose a major problem, (6) is pregnant
or trying to conceive, is breastfeeding, or is a woman of
childbearing potential not using a highly effective birth
control, (7) lactose intolerance, (8) known cardiovascular
disease (e.g. heart failure, myocardial infarction, conduc-
tion abnormalities including family history of QT pro-
longation, dehydration, hypovolaemia, bradycardia), or
electrolyte disturbances (hypokalaemia, hypomagnes-
aemia), or cerebrovascular disease, (9) a clinically signifi-
cant low white blood cell count or a drug-induced
leukopenia/neutropenia. and (10) a history of a con-
firmed neurogenic seizure in the last 3 months.
Recruitment
We plan to recruit up to 50 adults with TBI who have
been referred to a specialist service primarily for the
management of aggressive behaviour. Participants will
be recruited from outpatient clinics and hospital in-
patient settings.A patient who may be eligible for the study will be ini-
tially approached regarding the study by any healthcare
professional who is involved in their care providing that
the consultant for the team has agreed in principle to
patients under their care taking part in the study.
If a healthcare professional has a patient under their
care who they believe meets the eligibility criteria for
this study, they will briefly introduce the study to them.
Those patients who express an interest in taking part in
the study and give verbal agreement to discuss their eli-
gibility and possible enrolment into the trial with a
member of the research team will be given a Study In-
formation Sheet and a member of the research team will
go through the Study Information Sheet with them, an-
swering any questions. The patient’s agreement to be
contacted by a researcher will be documented in part 1
of a Referral and Screening Form.
Potential participants will be given at least 24 h
from receiving the Study Information Sheet to decide
whether to take part in the trial. If the patient does
decide to participate, they will be asked to complete a
Consent Form and assigned a screening number. The
date that the Study Information Sheet was given to
the patient and the date of consent will be recorded.
It will be made clear to the patient that they can
withdraw at any time during the trial, without having
to give a reason.
Written informed consent will include permission to
notify the patient’s general practitioner (GP) about the
enrolment of their patient into the trial, and to seek in-
formation about the patient from their named carer
where possible. A copy of the signed Consent Form will
be given to the patient. The original signed form will be
retained in the Investigator Site File.
Study participants will be recruited from four centres
in London and the South East of England: Imperial Col-
lege NHS Healthcare Trust, South West London and St.
George’s NHS Trust, Kent and Medway NHS Partner-
ship Trust and St George’s University Hospitals NHS
Foundation Trust.
Screening
A pre-randomisation assessment of eligibility will be
undertaken following consent by a check of the med-
ical records for the patient that are accessible at the
time of presentation to the specialist service. Where
no reason for ineligibility has been identified, a dis-
cussion with the patient (and their carer where ap-
propriate) will then take place to complete the
eligibility check. Once eligibility is confirmed, the re-
searcher will use the randomisation system to obtain
a randomisation code for the participant. Following
randomisation, the participant’s GP will be informed
of their enrolment into the trial via letter.
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As this is a feasibility study we have not carried out any for-
mal power calculation but estimate that it will be possible
to recruit 50 patients over 18 months from the four centres.
The sample size is also in keeping with recommendations
on feasibility trials for other conditions [21–23].
Study intervention, dosage and regime
A flexible oral dosing regimen of risperidone will be
used. Dosing will start with 1 mg once daily and be ti-
trated in 1-mg increments, not more than once every
7 days, to a maximum of 4 mg a day. The dose of risper-
idone in each capsule of active trial medication is 1 mg.
The titration schedule will be as follows: (1) one capsule
once daily (1 mg risperidone or matching placebo per
day), (2) one capsule twice daily (2 mg risperidone or
matching placebo per day), (3) two capsules at night and
one capsule in the morning (3 mg risperidone or match-
ing placebo per day), (4) two capsules twice daily (4 mg
risperidone or matching placebo per day). The dose may
also be reduced to a lower dose (minimum 1 mg once
daily) at any time.
During the weekly telephone or in-person follow-up
interview, the participant will complete the MOAS and
be asked to answer questions on their health state and if
they are experiencing any new or worsening side effects
(documented and acted upon as an adverse event where
reported). These data will be documented on a Trial
Medication Review Form and this form passed to the
participant’s prescriber (the principal investigator (PI) or
other medically qualified individual to whom the task is
delegated). The prescriber will decide whether to amend
the dose based on the participant’s response to the trial
medication as documented on this form.
We are using a lower dose of risperidone than is rec-
ommended in the British National Formulary (BNF) for
the treatment of schizophrenia for the following reasons:
(1) all the RCTs on intellectual disability and/or ASD
used a relatively small dose of risperidone, (2) in practice
clinicians use a low dose for treating aggression in TBI
and (3) a recent animal study has shown that chronic
use of high-dose risperidone as opposed to low-dose
may affect cognitive function in TBI rodents [24]. Also
there is a clinical belief (with no empirical evidence) that
at low dose, risperidone may have an anti-arousal/anti-
anxiety property which helps to improve aggression by
ameliorating the underlying anxiety or arousal which
may be triggering the aggressive behaviour.
Concomitant medication
It would be unethical to restrict the therapeutic options
of the clinical team; therefore, no restrictions will be im-
posed on the use of other treatments, except that those
who remain in the trial will not be prescribedrisperidone (aside from trial medication) and that pre-
scribing of other medication should be done as if the pa-
tient were taking the active medication (for example, if
they use an antipsychotic we will ask them to make sure
that the overall daily dose of antipsychotics does not ex-
ceed the BNF-recommended daily chlorpromazine
equivalent dose). As in clinical practice, medicines
known to prolong the QT interval, medicines that mod-
ify CYP2D6 activity, or medicines strongly inhibiting or
inducing CYP3A4 are prohibited.
Our approach will be primarily to record the use of all
other medication, documenting details of dosage, and
ensure the follow-up of all randomised participants, irre-
spective of the medication that they subsequently
receive.
Outcomes
Main outcome measure (baseline and weekly thereafter)
We will use the MOAS to assess improvement in ag-
gression. The MOAS is a simple but widely used four-
item scale that measures verbal aggression along with
physical aggression towards other people, property and
self. The MOAS is a valid and reliable instrument which
has been used in many pharmacological intervention
studies of aggression in different neuropsychiatric pa-
tient groups including TBI [19].
Other outcome measures (baseline and 12-week follow-up)
(1) Glasgow Outcome Scale-Extended version (GOS-E)
[25], which is a widely used global outcome measure of
social functioning following TBI, (2) Irritability Ques-
tionnaire (IRQ) [26], which has both a patient and a
carer version and will assess the degree of underlying ir-
ritability behind aggressive behaviour. Some believe that
in some people with TBI aggression is manifested as part
of an episodic dyscontrol and these patients may re-
spond better to a mood stabiliser. IRQ will help us to in-
vestigate any such differential treatment response,
Clinical Global Impression-Improvement (CGI-I) and
CGI-S (CGI-Severity) scales [27], (4) Udvalg for Kliniske
Undersøgelser (UKU) scale [28] to assess the adverse ef-
fects of risperidone. If any abnormal movement is dis-
covered then extrapyramidal adverse effects will be
explored further and (5) two widely used quality of life
(QoL) measures, namely the EuroQol five-dimension,
five-level questionnaire ( EQ-5D-5L) [29] and the 12-
item Short Form health survey (SF-12) [30], (6) mental
health of the patient will be assessed using the Hospital
Anxiety and Depression Scale (HADS) [31], which we
have standardised for use in patients with TBI [32], (7) if
available from the medical case notes at 12 weeks’
follow-up the following data will be collected; serum glu-
cose/glycosylated haemoglobin (HbA1c), lipid profile,
serum prolactin level, body weight and blood pressure.
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CCRF) specifically designed for this study to collect
demographic data such as age, gender, etc. but also other
relevant information such as timing, cause and severity
of TBI, past and present history of physical and mental
health problems and medication use, etc.
Where a carer has been identified and has consented
to provide information, they will be asked about the
participant’s level of aggression and irritability at 12-
week follow-up, using the MOAS and IRQ, respectively
(see Additional file 1 and Table 1).
Carer contact
The participant will be asked to provide details of a non-
professional carer if an outpatient, or identify a suitable
member of nursing staff if an in-patient. Where such an
individual is identified, they will be approached for con-
sent to provide information on the participant’s level of
aggression and irritability at baseline and 12-week
follow-up, using the MOAS and IRQ, respectively. Non-
professional carers will also be asked to complete the
‘Wellbeing’ section of the Carer Wellbeing and Support
Questionnaire (CWS) in relation to their own health
[33]. Patients who do not have a suitable carer may still
take part in the study.
Health economic data collection
We will use two health-related QoL measures, namely
the EQ-5D-5L and the SF-12 in order to assess theirTable 1 Assessment Schedule
Assessment Baseline 1-week 2-week 3-week 4-week
MOAS ✓ ✓ ✓ ✓ ✓
Current health state questions ✓ ✓ ✓ ✓ ✓
MOAS (carer report) a ✓
IRQ ✓
CGI ✓
GOS-E ✓
EQ-5D-5L ✓
SF-12 ✓
UKU ✓
HADS ✓
CSRI ✓
Concomitant medication ✓
Basic clinical & psychiatric
informationb
✓
Physical health measures ✓
IRQ (carer report) a ✓
CWS a ✓
awhere a carer is identified, and he/she consents to provide information
bwhere the data is already recorded in the participant’s medical recordssuitability for data collection in this sample. If found
useful in the feasibility study then one of these will be
used in a future full-scale RCT for calculating Quality-
adjusted Life Years (QALYs).
We will also measure service utilisation during the
study period using the Client Service Receipt Inventory
(CSRI) [34] at 12 weeks’ follow-up, which has been
widely used in previous studies of health economics.
This will allow us to capture non-medication-based in-
terventions including neurorehabilitation received by the
participants which may influence treatment outcome
from risperidone. As some patients with TBI will suffer
from memory problems, they may not be able to
complete all the sections in the CSRI, and information
may need to be gathered from their carers or from clin-
ical records. If that is the case, we will need to assess
which items can be collected from records, which will
require input from informants and whether there will be
enough informants available for the full RCT for this
purpose. It will not be possible to carry out a full cost-
effectiveness analysis in this feasibility study. However,
we will calculate indicative costs using descriptive
statistics.
Follow-up
We will assess participants at 12 weeks. We expect the
dose of risperidone to be stabilised within the first
3 weeks and its effect established within another 3 weeks
so that outcomes could be assessed at 12 weeks. We will5-week 6-week 7-week 8-week 9-week 10-week 11-week 12-week
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
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minimised for the full RCT.
Randomisation procedures
Remote web-based randomisation will be undertaken
through a fully automated service operated by an exter-
nal organisation ‘Sealed Envelope’. We will use random
permuted blocks stratified by study centre. Equal num-
bers of participants will be randomised to risperidone
and placebo. Randomisation of a participant at a site will
generate a randomisation code that corresponds to trial
medication held in the local pharmacy at the site where
the participant was recruited.
Concealment and unblinding procedure
Trial medication will be identified by a randomisation
code that corresponds to either risperidone or placebo,
labelled during manufacture and bottling of the capsules.
This will keep the patients, clinicians, carers and re-
searchers blind to the allocation of active drug and pla-
cebo. Three bottles of trial medication will have the
same randomisation code to allow sufficient supply for
one participant to complete 84 consecutive days. Trial
medication will be supplied to site pharmacies in blocks
sufficient to provide medication to six participants.
There will be a 24-h telephone number available for the
clinicians and research team if the randomisation code
needs to be broken. This information will help to design
pharmacy arrangement and associated logistics for the
full RCT which is likely to involve a large number of
centres.
Treatment procedures
Once randomisation has taken place, a study prescrip-
tion form containing the patient’s details (including their
randomisation code) will be signed by the site PI or the
patient’s usual prescriber (another medically qualified in-
dividual to whom the task is delegated), and sent to the
study site pharmacy. This prescription will allow for the
local site pharmacy to give the first and subsequent bot-
tles of trial medication to the participant (no further pre-
scription will be necessary for the second and third
bottles of trial medication from the medication pack to
be given out later in participation). An appropriate bottle
of trial medication will be selected and prepared for
collection.
Where the participant is an in-patient, the trial medi-
cation will be delivered to their ward, with the prior con-
sent of the ward manager. For in-patients, arrangements
will be made for the trial medication to be given by ward
staff in the same way as other prescribed medication
would be in this setting and it written up on the partici-
pant’s drug chart.Patients will be left with a telephone number for the
local research contact for any queries or to report any
suspected adverse effects. Someone from the research
team will telephone on the two consecutive days after
starting the treatment and weekly thereafter. Participants
will be asked to return all unused medication, which will
allow us to check for compliance.
Statistical analyses
As this is a feasibility study, any hypothesis testing at
this stage will be considered preliminary as the study is
not adequately powered. Instead we will work out the
standard deviation of the MOAS score at 12 weeks’
follow-up and as changes from baseline. These data will
inform a sample size calculation for our proposed full-
scale RCT in future, along with any other relevant pub-
lished information.
As this is a feasibility study we will only calculate 95%
confidence intervals of score changes in outcome mea-
sures from baseline to follow-up. We will ensure that
the way data are collected allows us to estimate Number
Needed to Treat (NNT) in the full RCT, which will use
an intention-to-treat analysis.
We will work out the range and mean score change in
MOAS from baseline to 12 weeks for those who have
scored ‘improved’ and ‘very much improved’ according
to the CGI-I scale. This information will determine what
effect size on MOAS corresponds to a clinically import-
ant improvement for an individual patient. This will in-
form the sample size calculation for the full RCT.
Post-trial Investigational Medicinal Product (IMP)
arrangements
Following a participant’s 12-week assessment, an email
will be sent to the referring clinician directly from the
randomisation system, informing them of the partici-
pant’s trial arm allocation. Where a participant has com-
pleted the participation period in full, this will allow for
arrangements to be made for the participant to continue
on risperidone if appropriate and desired. No further ris-
peridone will be supplied by the sponsor. The partici-
pant will be advised to contact their clinician to discuss
their trial arm allocation if they wish to know whether
they were taking the active or the placebo medication.
Assessment of participant compliance
Compliance includes both adherences to IMP and proto-
col procedures. Non-compliance to the protocol or trial
procedures should be documented by the investigator in
the participant CRF. Non-compliance data will be col-
lected as part of the assessments. This will include not-
ing missing assessment data and dating assessments to
determine when these occurred outside the study visit
window. In addition, the medication diary cards will be
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medication adherence. However, as this is a feasibility
study, no threshold criteria have been set for patient
withdrawal due to non-compliance.
Recording and reporting adverse events and reactions
Notification and reporting adverse events/reactions in
this clinical trial will be done according to procedures
described in Imperial College Healthcare Good Clinical
Practice.
Process evaluation
A parallel process evaluation using both qualitative and
quantitative methods will examine trial recruitment and
the feasibility and acceptability of trial procedures from
clinician and patient perspectives. The quantitative com-
ponent of the evaluation will involve sending out be-
spoke questionnaires designed for the study to
participants, their carers and the clinicians to collect
data on treatment adherence, non-pharmacological in-
terventions including psychological therapies and other
rehabilitation programmes, obstacles for recruitment
and retention, and support needed for the clinicians, pa-
tients and carers.
Semi-structured qualitative interviews will be con-
ducted with clinicians in each of the four sites. These
will be supplemented by semi-structured interviews with
a sample of 10 trial participants and/or their carers pur-
posively sampled to represent site and treatment
allocation.
The interview guides used in each context will be de-
veloped as the feasibility study progresses and will be
sensitive to emergent themes. These interviews will be
audio-recorded, transcribed and analysed using a the-
matic framework approach and managed using NVivo
[35] computer software. An initial framework will be
based on the study aims of how feasible it is to under-
take a definitive trial. This will be further developed
using analytic induction from early interviews and itera-
tively revised as data collection and analysis progress.
Project management
A Combined Independent Oversight Committee will be
in place prior to the start of the study and include an in-
dependent Chair and at least two other independent
members. This committee will provide overall supervi-
sion of the trial and ensure that it is being conducted in
accordance with protocol and current legislation. It will
also review trial data in order to identify patterns in the
data that may suggest the need to halt the trial.
A Trial Management Group will also be set up prior
to the start of the study, and will include those individ-
uals responsible for the day-to-day management of the
trial, such as the chief investigator (CI), representativePI(s) and trial management staff. In addition, a research
assistant and individual(s) who is/are able to contribute
a patient and/or wider public perspective will be in-
cluded. The role of the group will be to monitor all as-
pects of the conduct and progress of the trial, ensure
that the protocol is adhered to and take appropriate ac-
tion to safeguard participants and the quality of the trial
itself. The group should consider and act on the recom-
mendations of the Combined Independent Oversight
Committee, the Medicinal Health Regulatory Authority
(MHRA) and the Research Ethics Committee (REC).
We will set up a Patient Advisory Group which will
meet regularly and report back to the Trial Management
Group through one co-applicant who will also sit on the
Trial Management Group. The Patient Advisory Group
will also advise on accessible information leaflets, Con-
sent Forms and web-based newsletters for the project.
Additionally a patient co-applicant will be part of the
Trial Management Group.
Access to source data/documents
The investigator(s)/institution(s) will permit trial-related
monitoring, audits, REC review, and regulatory inspec-
tion(s), providing direct access to source data/docu-
ments. Trial participants are informed of this during the
informed consent discussion. Participants will consent to
provide access to their medical records.
Ethics and regulatory requirements
The sponsor will ensure that the trial protocol, Study In-
formation Sheets, Consent Forms, GP letter and submit-
ted supporting documents have been approved by the
MHRA and a main REC prior to any patient recruit-
ment. The protocol and all agreed substantial protocol
amendments will be documented and submitted for eth-
ical and, where necessary, regulatory approval prior to
implementation according to sponsor-specific Standard
Operating Procedures (SOPs).
Before the site can enrol patients into the trial, the
Trust Research and Development (R&D) for the site
must grant written permission. It is the responsibility of
the PI at each site to ensure that all subsequent amend-
ments gain the necessary approval. This does not affect
the individual clinician’s responsibility to take immediate
action if thought necessary to protect the health and
interest of individual patients. All PIs will be required to
have an up-to-date Good Clinical Practice training
certificate.
Within 90 days after the end of the trial, the CI/spon-
sor will ensure that the main REC and the MHRA are
notified that the trial has finished. If the trial is termi-
nated prematurely, those reports will be made within
15 days after the end of the trial. The CI will supply the
sponsor with a summary report of the clinical trial,
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REC within 1 year after the end of the trial.
Data handling and analysis
It will be the responsibility of the investigator as dele-
gated to ensure the accuracy of all data entered in the
CRFs. The delegation log will identify all those personnel
with responsibilities for data collection and handling, in-
cluding those who have access to the trial database.
Data will be collected using paper CRFs and then tran-
scribed onto a Microsoft Access database that is created
prior to the start of the trial. Data monitoring will be
carried out according to the trial-specific monitoring
plan. This details the quality control checks to be carried
out during site visits and when checking the database.
All serious adverse event and primary outcome data will
be checked and a random sample of the secondary out-
come data. The database will be stored on a network
drive at Imperial College London, which is backed up
daily. Data will only be input onto the database at Im-
perial College London from a computer owned by the
organisation that has access to the network drive.
At the end of the trial, data monitoring will be com-
pleted and the database ‘locked’ so that no further data
entry is possible. At this point the data will be given to
the trial statistician along with the randomisation list
stating whether participants were allocated to arm A or
arm B. The data will be analysed without knowledge of
which arm relates to the active trial medication.
Monitoring requirements for the trial
A trial-specific monitoring plan will be established based
on the trial risk assessment. The trial will be monitored
according to the agreed plan.
Dissemination
Dissemination will be ongoing. A project website at Im-
perial College London hyperlinked with the Royal Col-
lege of Psychiatrists, research network and relevant
service users’ organisations, will host relevant informa-
tion. A newsletter will be distributed twice a year to up-
date interested parties on the progress of the project and
the findings of each stage. It will also maintain interest
in the project and help facilitate recruitment. Careful at-
tention will be paid to providing accessible information
for TBI patients. Accessible newsletters will be distrib-
uted via service-user organisations and the final guides
and reports will be available in accessible format.
One conference will be organised in London at the
Royal College of Psychiatrists’ conference venue at the end
of the project to disseminate findings. This event will be
free of charge to attend and open to a wide range of dele-
gates. A summary report will be produced and sent to a
wide range of stakeholders. Papers will be prepared forpublication in high-impact peer-reviewed journals. Find-
ings of the study will also be presented in local, national
and international meetings and conferences. The results
of the trial will be posted by the sponsor on EudraCT and
made available to the public via the EU Clinical Trials
Register. Care will be paid to disseminating to care staff
and family carers via appropriate organisations such as
Headway. If requested, each study participant will be sent
a personal letter thanking them for their involvement in
the study which will also provide a short summary of the
study findings and details of how further information
about the project can be obtained.
Discussion
Aggressive behaviour causes immense distress among
people with TBI and their families, sometimes leading to
family breakdown. This is a hidden disability within society
as many of these patients suffer from lack of appropriate
intervention and service provision. These patients believe
that an effective intervention is urgently needed to help
improve their quality of life. An appropriately designed
RCT will provide much needed evidence to support a par-
ticular type of intervention such as drug therapy.
Each year 1.4 million people attend Accident and
Emergency departments in England and Wales with TBI
and a high proportion of them develop long-lasting con-
sequences including irritable and aggressive behaviour
[1–6]. This is proving to be a major burden for the
NHS. A clinically and cost-effective intervention will re-
duce this burden on the NHS for which appropriately
conducted RCTs are mandatory. This also has the poten-
tial to reduce the need for mental health service, in-
patients and emergency departments, where these pa-
tients are likely to present in the absence of an appropri-
ate intervention.
Despite the high prevalence of neuropsychiatric and
neurobehavioural problems after TBI [7–9], these pa-
tients often do not receive appropriate treatment and in
most cases do not receive any treatment largely because
of lack of awareness of these problems within the med-
ical fraternity but also because of lack of appropriate ser-
vices [36]. As a result the neuropsychiatric sequelae of
TBI result in ‘hidden disability’ in which patients and
their families suffer in silence in the absence of any
meaningful intervention.
One reason for carrying out this feasibility study is to
assess the rate of recruitment and attrition as this sort of
RCT has never been carried out involving this patient
group in the UK or elsewhere in the world for that mat-
ter [10–12]. Therefore, there may be an expected degree
of apprehension on the part of patients, their carers and
the practicing clinicians to take part in a blinded study
which will include placebo as a possible intervention
[37]. However, our initial discussion with patient groups
Deb et al. Trials  (2018) 19:325 Page 9 of 10and clinicians indicates that many of them are willing to
take part in such a study. As this is completely un-
charted territory (as no large-scale properly designed
RCT exists) [38], it is necessary to carry out a feasibility
study like the one we are proposing before embarking
on a full-scale RCT.
This feasibility study will assess the willingness of the
clinicians to recruit into the study in practice, among a
group of clinicians who have already agreed in principle
to recruit. Issues around recruitment will be explored,
such as any obstacle that can be addressed, and any pro-
cedure that can be used to identify potential participants.
The feasibility study will also help to refine our estimates
of the number of eligible patients for recruitment in
each centre, which will allow us subsequently to deter-
mine how many centres we need to recruit from for the
full RCT.
Apart from the information mentioned earlier on re-
cruitment rate, retention, etc., this feasibility study will
also inform whether randomisation is possible for a fu-
ture definitive RCT, what factors should be considered
for clustering, how to stratify the sample, applicability of
the outcome measures, deciding on primary and second-
ary outcome measures, acceptability of the intervention
and if any revision is needed for their future application.
and to determine what should be an ideal follow-up
period. During the study we shall also network widely
with organisations providing service for patients with
TBI in order to assess whether recruitment for a re-
quired number of participants is possible in a future de-
finitive RCT [22]. We shall also network with other
professionals working in the field in order to involve
them in a future RCT if necessary.
Success of this project will be evident in completion of
the study as per timetable. The principal challenges will
be recruitment of the study sample, maintaining engage-
ment with treatment and minimising loss to follow-up.
Should the rate of recruitment or follow-up be below
that stated in the proposal we will consider available
strategies [23]. We will also explore the possibility of
recruiting from other centres within the consortium as a
large-scale definitive RCT is urgently needed in this field
in order to develop more effective responses to the chal-
lenging problem of management of aggression in pa-
tients with TBI.
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